![Loading...](https://link.springer.com/static/c4a417b97a76cc2980e3c25e2271af3129e08bbe/images/pdf-preview/spacer.gif)
-
Article
Open AccessDiagnostic leukapheresis reveals distinct phenotypes of NSCLC circulating tumor cells
Circulating tumor cells (CTCs) hold immense promise for unraveling tumor heterogeneity and understanding treatment resistance. However, conventional methods, especially in cancers like non-small cell lung canc...
-
Article
Open AccessHERC5 downregulation in non-small cell lung cancer is associated with altered energy metabolism and metastasis
Metastasis is the leading cause of cancer-related death in non-small cell lung cancer (NSCLC) patients. We previously showed that low HERC5 expression predicts early tumor dissemination and a dismal prognosis ...
-
Article
Open AccessClinical applications of circulating tumor cells in patients with solid tumors
The concept of liquid biopsy analysis has been established more than a decade ago. Since the establishment of the term, tremendous advances have been achieved and plenty of methods as well as analytes have bee...
-
Article
Open AccessComparative analysis of EpCAM high-expressing and low-expressing circulating tumour cells with regard to their clonal relationship and clinical value
Circulating tumour cells (CTCs) are mainly enriched based on the epithelial cell adhesion molecule (EpCAM). Although it was shown that an EpCAM low-expressing CTC fraction is not captured by such approaches, k...
-
Article
Open AccessLiquid biopsy for monitoring of tumor dormancy and early detection of disease recurrence in solid tumors
Cancer is one of the three leading causes of death worldwide. Even after successful therapy and achieving remission, the risk of relapse often remains. In this context, dormant residual cancer cells in seconda...
-
Article
Open AccessClinical applications and utility of cell-free DNA-based liquid biopsy analyses in cervical cancer and its precursor lesions
Human papilloma virus (HPV) is an infectious carcinogenic agent. Nearly all cervical cancers are positive for one of the high-risk HPV subtypes. Although the introduction of the HPV vaccines in many countries ...
-
Article
Open AccessFunctional analysis of circulating tumour cells: the KEY to understand the biology of the metastatic cascade
Metastasis formation is the main cause of cancer-related death in patients with solid tumours. At the beginning of this process, cancer cells escape from the primary tumour to the blood circulation where they ...
-
Article
Open AccessTumorigenic circulating tumor cells from xenograft mouse models of non-metastatic NSCLC patients reveal distinct single cell heterogeneity and drug responses
Circulating tumor cells (CTCs) are liquid biopsies that represent micrometastatic disease and may offer unique insights into future recurrences in non-small cell lung cancer (NSCLC). Due to CTC rarity and limi...
-
Article
Open AccessAggressive variants of prostate cancer: underlying mechanisms of neuroendocrine transdifferentiation
Prostate cancer is a hormone-driven disease and its tumor cell growth highly relies on increased androgen receptor (AR) signaling. Therefore, targeted therapy directed against androgen synthesis or AR activati...
-
Article
Open AccessMolecular mechanisms of cancer metastasis via the lymphatic versus the blood vessels
Cancer metastasis is the process by which primary cancer cells invade through the lymphatic or blood vessels to distant sites. The molecular mechanisms by which cancer cells spread either through the lymphatic...
-
Article
Open AccessClinical relevance of blood-based ctDNA analysis: mutation detection and beyond
Cell-free DNA (cfDNA) derived from tumours is present in the plasma of cancer patients. The majority of currently available studies on the use of this circulating tumour DNA (ctDNA) deal with the detection of ...
-
Article
Open AccessEGFR as a stable marker of prostate cancer dissemination to bones
Prostate cancer (PCa) is among the most commonly diagnosed malignancies in men. Although 5-year survival in patients with localised disease reaches nearly 100%, metastatic disease still remains incurable. Ther...
-
Article
Open AccessMolecular profiling of an osseous metastasis in glioblastoma during checkpoint inhibition: potential mechanisms of immune escape
Peripheral metastases of glioblastoma (GBM) are very rare despite the ability of GBM cells to pass through the blood-brain barrier and be disseminated through the peripheral blood. Here, we describe a detailed...
-
Article
Unravelling tumour heterogeneity by single-cell profiling of circulating tumour cells
Single-cell technologies have contributed to unravelling tumour heterogeneity, now considered a hallmark of cancer and one of the main causes of tumour resistance to cancer therapies. Liquid biopsy (LB), defin...
-
Article
Open AccessClonality of circulating tumor cells in breast cancer brain metastasis patients
The incidence of brain metastases in breast cancer (BCBM) patients is increasing. These patients have a very poor prognosis, and therefore, identification of blood-based biomarkers, such as circulating tumor c...
-
Article
Open AccessElevated serum RAS p21 is an independent prognostic factor in metastatic breast cancer
An important component of the RAS signalling pathway, the RAS p21 oncogene, is frequently hyperactivated in breast cancer. Its expression in tumor tissue has been linked to poor clinical outcome. This study wa...
-
Article
Open AccessAdvances in liquid biopsy approaches for early detection and monitoring of cancer
Progress in sensitive analytical approaches has opened new avenues for the detection of cells or products such as circulating cell-free DNA released by tumors. These ‘liquid biopsies’ are being explored in cli...
-
Article
11th International Symposium on Minimal Residual Cancer (ISMRC): 3–5 May 2018, Montpellier, France
-
Article
Abstracts from the 11th International Symposium on Minimal Residual Disease, 3–5 May 2018, Montpellier, France
-
Article
Profiling circulating tumour cells and other biomarkers of invasive cancers
During cancer progression, many tumours shed circulating tumour cells (CTCs) and other biomarkers into the bloodstream. The analysis of CTCs offers the prospect of collecting a liquid biopsy from a patient’s b...